BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1163@pharmaconomics
DTSTAMP:20260707T040806Z
DTSTART;VALUE=DATE:20260226
DTEND;VALUE=DATE:20260227
SUMMARY:ARGX Phase 3 — VYVGART
DESCRIPTION:Phase 3 trial results for VYVGART in primary immune thrombocytopenia (ITP) are due Feb 26\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1697862/000110465926045083/tm2612048d1_ex99-1.htm\n\nTrack it: https://www.pharmaconomics.com/e/1163
URL:https://www.pharmaconomics.com/e/1163
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:ARGX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR